|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's Range||47.11 - 47.85|
|52 Week Range||40.78 - 57.40|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||15.87|
|Earnings Date||Feb 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.33|
Today's bell ringers are Yeti Holdings with CEO and president Matthew Reintjes at the NYSE, and StoneCo Ltd. with CEO Thiago Piau at the Nasdaq.
SWINDON, United Kingdom, Jan. 15, 2019 -- Sensata Technologies (NYSE:ST) today announced that it will disclose its fourth quarter and full year 2018 financial results on.
The Sensata Technologies Foundation, launched in November 2017, announced its first annual grant award recipients for funding year 2019. The Foundation also announced that the grant application for the 2019-2020 grant cycle is now available on the Sensata Foundation website and will close on Friday, June 28, 2019. The Sensata Foundation’s Annual Grants are 12-month grants for new or existing projects related to one or more of the Foundation’s priorities of STEM and Community.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
At Insider Monkey, we pore over the filings of more than 700 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of September 30. In […]
The “Internet of Things” is already a fairly well-known term, but by next year, I expect it will be a phrase used in every household. The reach of the IoT is massive, which should might have investors asking themselves what are some good Internet of Things stocks to buy? IoT includes the commonly thought of devices like smartphones and televisions, as well as new possibilities such as thermostats, automobiles and even street lights.
The U.K.-based maker of sensors and controls continues to make non-auto M&A deals. Investor pessimism over the global auto market has hurt the stock.
Sensata (ST) delivered earnings and revenue surprises of 0.00% and 1.42%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Swindon, Britain-based company said it had profit of 88 cents per share. Earnings, adjusted for non-recurring costs, were 91 cents per share. The results met Wall Street expectations. The average estimate ...
SWINDON, United Kingdom, Oct. 30, 2018 -- Sensata Technologies (NYSE:ST), a global industrial technology company and a leading provider of sensors, today announced financial.
Sensata Technologies Holding PLC (ST) was incorrectly omitted from the Biggest 1,000 Stocks tables published from March 29 to Oct. 20. As of Sept. 28, the one-year return of Union Street Partners Value Fund Advisor Class (USPFX) was 16.
Sensata (ST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors’ mounting worries about the health of the global auto market have dented shares of Sensata Technologies. That could be an opportunity for patient investors.
The once red-hot semiconductor sector is slowing down, with one team of analysts cutting their stock estimates for the first time in three years. In a recent research note, Morgan Stanley analyst Craig Hettenbach lowered his estimates for the chip sector in the fourth quarter and the year ahead. Hettenbach also reduced his price forecast for seven stocks including Qorvo Inc. ( QRVO), Microchip Technology Inc. ( MCHP), and TE Connectivity Ltd. ( TEL).
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Sensata Technologies Holding PLC (NYSE:ST), with a market cap of US$8.61b, often Read More...
Medical Prognosis Institute A/S and Oncology Venture AB (ST) ("OV" or the "Company") and Oncology Venture US Inc today announced that the US Food and Drug Administration (FDA) has accepted its Investigational Device Exemption (IDE) and its Investigational New Drug Application (IND) to begin a Phase 2 clinical trial in advanced ovarian cancer with 2X-121 -a PARP inhibitor- using it`s Drug Response Predictor - DRP - to select patients with high likelihood of responding to the treatment. The 2X-121 DRP has a gene signature consisting of more than 400 genes.